The license agreement grants PranaX access to a core patent portfolio covering exosome manufacturing, engineering and therapeutic applications through a technology licensing agreement. This agreement ...
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. It’s not your imagination. Whether you’re scanning ...
The financial trajectory of the exosome therapy market is decoupling from the broader, slower-growing regenerative medicine ...
As described in the publication, each treatment dose consisted of 1 ml of exosome solution, containing a defined range of exosome particle numbers, mixed with 5 ml of saline. The solution was ...
SHENZHEN, China, Sept. 16, 2025 /PRNewswire/ -- Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results